Senju gains Chinese rights to ophthalmic gatifloxacin
This article was originally published in Scrip
Kyorin Pharmaceutical has granted fellow Japanese company Senju the exclusive right to market an ophthalmic solution of gatifloxacin in China.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.